Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

References

• JemalABrayFCenterMMGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• EdwardsBKHoweHLRiesLAAnnual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burdenCancer200294102766279212173348
   PubMed Web of Science ®Google Scholar
• SiegelRDesantisCJemalAColorectal cancer statistics, 2014CA Cancer J Clin201464210411724639052
   PubMed Web of Science ®Google Scholar
• BrennerHKloorMPoxCPColorectal cancerLancet201438399271490150224225001
   PubMed Web of Science ®Google Scholar
• FolprechtGCunninghamDRossPEfficacy of 5-fluo-rouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trialsAnn Oncol20041591330133815319237
   PubMed Web of Science ®Google Scholar
• RosenLSVEGF-targeted therapy: therapeutic potential and recent advancesOncologist200510638239115967832
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus iri-notecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• GiantonioBJCatalanoPJMeropolNJBevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol200725121539154417442997
   PubMed Web of Science ®Google Scholar
• BennounaJSastreJArnoldDContinuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trialLancet Oncol2013141293723168366
   PubMed Web of Science ®Google Scholar
• TebbuttNCMurphyFZanninoDRisk of arterial thromboem-bolic events in patients with advanced colorectal cancer receiving bevacizumabAnn Oncol20112281834183821273347
   PubMed Web of Science ®Google Scholar
• Van CutsemERiveraFBerrySSafety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyAnn Oncol200920111842184719406901
   PubMed Web of Science ®Google Scholar
• KabbinavarFFSchulzJMcCleodMAddition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trialJ Clin Oncol200523163697370515738537
   PubMed Web of Science ®Google Scholar
• KabbinavarFHurwitzHIFehrenbacherLPhase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancerJ Clin Oncol2003211606512506171
   PubMed Web of Science ®Google Scholar
• JacksonNABarruecoJSoufi-MahjoubiRComparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib studyCancer2009115122617262919382200
   PubMed Web of Science ®Google Scholar
• TolJKoopmanMCatsAChemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancerN Engl J Med2009360656357219196673
   PubMed Web of Science ®Google Scholar
• VenderboschSDoornebalJTeerenstraSOutcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG)Acta Oncol201251783183922794910
   PubMed Web of Science ®Google Scholar
• TebbuttNCWilsonKGebskiVJCapecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX StudyJ Clin Oncol201028193191319820516443
   PubMed Web of Science ®Google Scholar
• PriceTJZanninoDWilsonKBevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin CAnn Oncol20122361531153622039086
   PubMed Web of Science ®Google Scholar
• KabbinavarFFHurwitzHIYiJAddition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trialsJ Clin Oncol200927219920519064978
   PubMed Web of Science ®Google Scholar
• CassidyJSaltzLBGiantonioBJEffect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studiesJ Cancer Res Clin Oncol2010136573774319904559
   PubMed Web of Science ®Google Scholar
• CunninghamDLangIMarcuelloEBevacizumab plus capecit-abine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialLancet Oncol201314111077108524028813
   PubMed Web of Science ®Google Scholar
• KozloffMYoodMUBerlinJClinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort studyOncologist200914986287019726453
   PubMed Web of Science ®Google Scholar
• KozloffMFBerlinJFlynnPJClinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort studyOncology2010785/632933920733336
   PubMed Web of Science ®Google Scholar
• GrotheyASargentDGoldbergRMSurvival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatmentJ Clin Oncol20042271209121415051767
   PubMed Web of Science ®Google Scholar
• BendellJCBekaii-SaabTSCohnALTreatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort studyOncologist201217121486149523015662
   PubMed Web of Science ®Google Scholar
• MeyerhardtJALiLSanoffHKEffectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancerJ Clin Oncol201230660861522253466
   PubMed Web of Science ®Google Scholar
• ShankaranVMummyDKoeplLAdverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancerClin Colorectal Cancer201312320421323276520
   PubMed Web of Science ®Google Scholar
• SolomonDSue BrownABrummel-SmithKNational Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-makingJ Am Geriatr Soc200351101490149414511174
   PubMed Web of Science ®Google Scholar
• ExtermannMAaproMBernabeiRUse of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)Crit Rev Oncol Hematol200555324125216084735
   PubMed Web of Science ®Google Scholar
• BononiAInnoABorghiMThe prognostic value of rapid screening tests (RST) in geriatric assessment of patients with cancer over 70J Clin Oncol201331Suppl Abstr 9554
   Google Scholar
• SclafaniFCunninghamDBevacizumab in elderly patients with metastatic colorectal cancerJ Geriatr Oncol201451788824484722
   PubMed Web of Science ®Google Scholar